• All IHC stains will include a positive control tissue

• CD123 identifies blastic plasmacytoid dendritic cell (BPDC) neoplasms, which tend to involve multiple sites, with predilection for skin (almost 100% of cases), followed by bone marrow (60-90%) and other sites. 10-20% of cases are associated with or develop into AML
• CD 123 is most useful in an antibody panel designed to detect BPDC neoplasms, which are CD4+, CD56+, CD68+ (50% have cytoplasmic dot staining), and TdT (33% positive). Tumors that share some but not all immunophenotypic features of BPDC are better classified as "acute leukemia of ambiguous lineage"

Submit a formalin-fixed, paraffin embedded tissue block

Formalin-fixed, paraffin embedded (FFPE) tissue block

FFPE tissue section mounted on a charged, unstained slide

Ambient (preferred)

• Unlabeled/mislabeled block
• Insufficient tissue
• Slides broken beyond repair

Immunohistochemical staining and microscopic examination

If requested, an interpretive report will be provided

Specifications

• CD123 antibody reacts with IL-3 receptor alpha chain which is expressed on normal plasmacytoid dendritic cells
• CD 123 reactivity with does not occur on other hematopoietic progenitor cells, but has not been extensively studied

Staining pattern

• Membrane -based staining

References

1. WHO (2008) classification of tumors of hematopoietic and lymphoid tissues, p145-147.